These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 11848442)

  • 1. A cyclic pentapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation.
    Orning L; Fischer PM; Hu CK; Agner E; Engebretsen M; Husbyn M; Petersen LB; Orvim U; Llinas M; Sakariassen KS
    Thromb Haemost; 2002 Jan; 87(1):13-21. PubMed ID: 11848442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solution structure of the N-terminal EGF-like domain from human factor VII.
    Muranyi A; Finn BE; Gippert GP; Forsén S; Stenflo J; Drakenberg T
    Biochemistry; 1998 Jul; 37(30):10605-15. PubMed ID: 9692950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of O-fucosylation on the first EGF-like domain from human blood coagulation factor VII.
    Kao YH; Lee GF; Wang Y; Starovasnik MA; Kelley RF; Spellman MW; Lerner L
    Biochemistry; 1999 Jun; 38(22):7097-110. PubMed ID: 10353820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational transitions in factor VIIa: can we stabilize the inactive form of the enzyme?
    De CR
    Thromb Haemost; 2002 Jan; 87(1):4-6. PubMed ID: 11848455
    [No Abstract]   [Full Text] [Related]  

  • 6. The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis.
    Norledge BV; Petrovan RJ; Ruf W; Olson AJ
    Proteins; 2003 Nov; 53(3):640-8. PubMed ID: 14579355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A peptide sequence from the EGF-2 like domain of FVII inhibits TF-dependent FX activation.
    Orning L; Stephens RW; Petersen LB; Hamers MJ; Stormorken H; Sakariassen KS
    Thromb Res; 1997 Apr; 86(1):57-67. PubMed ID: 9172287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of porcine factor VII, X and comparison with human factor VII, X.
    Chen Y; Qiao J; Tan W; Lu Y; Qin S; Zhang J; Li S; Bu H; Cheng J
    Blood Cells Mol Dis; 2009; 43(1):111-8. PubMed ID: 19286401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
    Parlow JJ; Case BL; Dice TA; Fenton RL; Hayes MJ; Jones DE; Neumann WL; Wood RS; Lachance RM; Girard TJ; Nicholson NS; Clare M; Stegeman RA; Stevens AM; Stallings WC; Kurumbail RG; South MS
    J Med Chem; 2003 Sep; 46(19):4050-62. PubMed ID: 12954058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four loops of the catalytic domain of factor viia mediate the effect of the first EGF-like domain substitution on factor viia catalytic activity.
    Jin J; Perera L; Stafford D; Pedersen L
    J Mol Biol; 2001 Apr; 307(5):1503-17. PubMed ID: 11292356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterisation of vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoi.
    Oliveira DG; Alvarez-Flores MP; Lopes AR; Chudzinski-Tavassi AM
    Thromb Haemost; 2012 Sep; 108(3):570-8. PubMed ID: 22782262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
    J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicted solution structure of zymogen human coagulation FVII.
    Perera L; Darden TA; Pedersen LG
    J Comput Chem; 2002 Jan; 23(1):35-47. PubMed ID: 11913388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of monoclonal anti-human factor VII antibody (B101/B1) that recognized three-dimensional structures near Arg at position 79 in the first EGF-like domain.
    Takamiya O
    Thromb Haemost; 1998 Jan; 79(1):104-9. PubMed ID: 9459333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the human tissue factor/FVIIa complex as an antithrombotic target and the discovery of a synthetic peptide.
    Sakariassen KS; Orning L
    Future Cardiol; 2007 May; 3(3):249-62. PubMed ID: 19804217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a factor VII molecule carrying a mutation in the second epidermal growth factor-like domain.
    Kavlie A; Orning L; Grindflek A; Stormorken H; Prydz H
    Thromb Haemost; 1998 Jun; 79(6):1136-43. PubMed ID: 9657438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. III. Instantaneous inhibition by compound 48/80 of tissue factor-initiated extrinsic coagulation is mediated by the downregulation of factor VII activation.
    Chu AJ; Wang ZG; Fox MJ
    Arch Biochem Biophys; 2000 May; 377(2):357-65. PubMed ID: 10845714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linear analogues derived from the first EGF-like domain of human blood coagulation factor VII: enhanced inhibition of FVIIa/TF complex activity by backbone modification through aspartimide formation.
    Husbyn M; Orning L; Cuthbertson A; Fischer PM
    J Pept Sci; 1999 Jul; 5(7):323-9. PubMed ID: 10442768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.